MADISON, Wis., July 18, 2017 /PRNewswire/ -- Invenra today announced a collaboration with Merck, known as MSD outside the United States and Canada, to discover fully human therapeutic antibodies against an unnamed target of interest to Merck. Financial details of the deal were not disclosed.
"We are excited to be working with this first rate team in Merck," said Dr. Roland Green, CEO of Invenra. "Invenra's ability to test antibodies for a functional phenotype early in the screening process combined with Merck's established role as a leader in this field will advance the science regarding difficult to address targets. This collaboration marks a significant milestone for Invenra in its mission to advance the field of antibody discovery through its ultra-high throughput mAbSeq™ technology."
About mAbSeq™ and B-Body™ Technologies Invenra's proprietary platform is based on ultra-high throughput technology allowing function forward screening of full-length antibodies using Invenra's mAbSeq™ technology, where antibodies can be directly and quickly interrogated in a multi-plexed fashion with a diverse set of immunotypic and biologically relevant assays. The Invenra technology allows rapid identification of high affinity mAbs with broad epitope coverage while simultaneously performing direct phenotypic screening to isolate those mAbs with the most relevant biological activity. B-Body™ is a novel bispecific format that can also be screened in large numbers using mAbSeq™ for bispecific combinations with desired phenotypic characteristics.
About Invenra, Inc.
Invenra, Inc., is an antibody discovery and development company focused on bispecific antibodies for immuno-oncology. The bispecifics are being developed with Invenra's B-Body™ technology, which uses a novel bispecific format. Hundreds of B-Body™ bispecifics can be assessed daily with high-throughput screening. Invenra has developed its own pipeline of bispecifics and has several strategic alliances in which antibody drug developers use Invenra's high-throughput screening technologies to identify molecules with biological relevance.
The competitive nature and blockbuster potential of antibody therapeutics development for immuno-oncology makes speed to market critical. Yet often time is wasted on developing antibodies that turn out to be of no use, have poor drug characteristics or that cannot be efficiently manufactured. Invenra's mAbSeq™ high-throughput screening technology and B-Body™ bispecific format enable simultaneous assessment of antibody binding and function in cell-based assays.
Invenra is based in Madison, Wisconsin.
Company Contact
Dr. Roland GreenCEOInvenra, Inc.+1 (608) [email protected]
HEADQUARTERS505 S Rosa Rd, Ste 235Madison, WI 53719
Media Contacts
David SchullRusso Partners+1 (212) [email protected]
Amiad FinkelthalRusso Partners+1 (646) [email protected]
Advertisement
"We are excited to be working with this first rate team in Merck," said Dr. Roland Green, CEO of Invenra. "Invenra's ability to test antibodies for a functional phenotype early in the screening process combined with Merck's established role as a leader in this field will advance the science regarding difficult to address targets. This collaboration marks a significant milestone for Invenra in its mission to advance the field of antibody discovery through its ultra-high throughput mAbSeq™ technology."
Advertisement
About mAbSeq™ and B-Body™ Technologies Invenra's proprietary platform is based on ultra-high throughput technology allowing function forward screening of full-length antibodies using Invenra's mAbSeq™ technology, where antibodies can be directly and quickly interrogated in a multi-plexed fashion with a diverse set of immunotypic and biologically relevant assays. The Invenra technology allows rapid identification of high affinity mAbs with broad epitope coverage while simultaneously performing direct phenotypic screening to isolate those mAbs with the most relevant biological activity. B-Body™ is a novel bispecific format that can also be screened in large numbers using mAbSeq™ for bispecific combinations with desired phenotypic characteristics.
About Invenra, Inc.
Invenra, Inc., is an antibody discovery and development company focused on bispecific antibodies for immuno-oncology. The bispecifics are being developed with Invenra's B-Body™ technology, which uses a novel bispecific format. Hundreds of B-Body™ bispecifics can be assessed daily with high-throughput screening. Invenra has developed its own pipeline of bispecifics and has several strategic alliances in which antibody drug developers use Invenra's high-throughput screening technologies to identify molecules with biological relevance.
The competitive nature and blockbuster potential of antibody therapeutics development for immuno-oncology makes speed to market critical. Yet often time is wasted on developing antibodies that turn out to be of no use, have poor drug characteristics or that cannot be efficiently manufactured. Invenra's mAbSeq™ high-throughput screening technology and B-Body™ bispecific format enable simultaneous assessment of antibody binding and function in cell-based assays.
Invenra is based in Madison, Wisconsin.
Company Contact
Dr. Roland GreenCEOInvenra, Inc.+1 (608) [email protected]
HEADQUARTERS505 S Rosa Rd, Ste 235Madison, WI 53719
Media Contacts
David SchullRusso Partners+1 (212) [email protected]
Amiad FinkelthalRusso Partners+1 (646) [email protected]
View original content:http://www.prnewswire.com/news-releases/invenra-enters-collaboration-agreement-with-merck-to-identify-therapeutic-antibodies-against-challenging-target-300489607.html
SOURCE Invenra, Inc.
